Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BNTC Stock Summary
Top 10 Correlated ETFs
BNTC
In the News
Benitec Biopharma to Present at the OPMD International Conference
HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A.
Penny Stocks To Buy Now? 4 Biotech Stocks To Watch Before July 2022
Biotech penny stocks to watch right now. The post Penny Stocks To Buy Now?
Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference
HAYWARD, Calif., Sept. 13, 2021 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A.
Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022
HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an overview of the key elements of the BB-301 Phase 1b/2a clinical trial design.
Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals
HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an update on the ongoing analyses of the large animal subjects treated with BB-301 in the Pilot Dosing Study.
Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million
HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 3,036,366 shares of common stock of the Company at a price to the public of $4.25 per share, less underwriting discounts and commissions.
Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock
HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that it has entered into an underwriting agreement with H.C.
BNTC Stock Price Increased 190.28%: Why It Happened
The stock price of Benitec Biopharma Inc (NASDAQ: BNTC) increased by 190.28% today. This is why it happened.
Benitec BioPharma Shares Rally: Technical Levels To Watch
Benitec BioPharma Inc. (NASDAQ: BNTC) shares rallied Tuesday following a filing by Morgan Stanley that showed the bank increased its stake in the Australian biotechnology company by 5.2%. The stock gained 190.28% in Tuesday's session, closing at $9.26, and was giving back 11.12% to $8.23 in after-hours trading at last check.
What Will the Stock Market Do Today? 3 Big Stories to Watch.
What will the stock market do today? All eyes are on President Joe Biden and his spending plan, as well as Covid-19 vaccine news.
BNTC Financial details
BNTC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 224.55 | 1.61 | 0.23 | 0.15 | 0.05 | |
Net income per share | 56.89 | -138.19 | -54.54 | -38.62 | -14.12 | |
Operating cash flow per share | 95.05 | -125.44 | -50.79 | -33.08 | -13 | |
Free cash flow per share | 87.04 | -127.02 | -51.66 | -33.1 | -13 | |
Cash per share | 313.95 | 163.18 | 78.24 | 8.45 | 1.79 | |
Book value per share | 328.79 | 170.43 | 79.19 | 6 | 0.15 | |
Tangible book value per share | 328.79 | 170.43 | 79.19 | 6 | 0.15 | |
Share holders equity per share | 328.79 | 170.43 | 79.19 | 6 | 0.15 | |
Interest debt per share | 0 | 6.74 | 0.82 | 1.75 | 0.43 | |
Market cap | 13.82M | 8.08M | 18.26M | 9.48M | 5.63M | |
Enterprise value | -1.88M | -1.32M | -1.3M | 6.23M | 3.71M | |
P/E ratio | 4.82 | -0.97 | -1.32 | -0.51 | -0.29 | |
Price to sales ratio | 1.22 | 83.27 | 309.41 | 129.85 | 75.02 | |
POCF ratio | 2.88 | -1.07 | -1.42 | -0.6 | -0.31 | |
PFCF ratio | 3.15 | -1.06 | -1.4 | -0.6 | -0.31 | |
P/B Ratio | 0.83 | 0.79 | 0.91 | 3.29 | 27.85 | |
PTB ratio | 0.83 | 0.79 | 0.91 | 3.29 | 27.85 | |
EV to sales | -0.17 | -13.59 | -22.04 | 85.32 | 49.44 | |
Enterprise value over EBITDA | -0.87 | 0.17 | 0.1 | -0.35 | -0.2 | |
EV to operating cash flow | -0.39 | 0.17 | 0.1 | -0.39 | -0.21 | |
EV to free cash flow | -0.43 | 0.17 | 0.1 | -0.39 | -0.21 | |
Earnings yield | 0.21 | -1.03 | -0.75 | -1.96 | -3.48 | |
Free cash flow yield | 0.32 | -0.94 | -0.72 | -1.68 | -3.2 | |
Debt to equity | 0 | 0.04 | 0.01 | 0.28 | 2.77 | |
Debt to assets | 0 | 0.03 | 0.01 | 0.14 | 0.13 | |
Net debt to EBITDA | -7.27 | 1.2 | 1.47 | 0.18 | 0.1 | |
Current ratio | 7.1 | 9.51 | 15.05 | 1.9 | 0.94 | |
Interest coverage | 0 | 0 | 2.27K | -557.94 | -578.21 | |
Income quality | 1.84 | 0.91 | 0.92 | 0.87 | 0.92 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.59 | 57.39 | 110.37 | 91.04 | 85.09 | |
Research and developement to revenue | 0.19 | 30.94 | 118.98 | 154.41 | 170.32 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | -0.08 | 0.01 | 0.02 | 0 | 0 | |
Capex to revenue | -0.04 | -0.98 | -3.75 | -0.18 | -0.01 | |
Capex to depreciation | -2.55 | -0.25 | -0.52 | -0.03 | 0 | |
Stock based compensation to revenue | 0.08 | 2.44 | 10.75 | 11.92 | 6.03 | |
Graham number | 648.75 | 727.96 | 311.75 | 72.18 | 6.8 | |
ROIC | 0.16 | -0.75 | -0.66 | -4.04 | -14.46 | |
Return on tangible assets | 0.15 | -0.72 | -0.64 | -3.11 | -4.38 | |
Graham Net | 299.3 | 149.35 | 72.9 | 2.02 | -1.25 | |
Working capital | 16.09M | 9.67M | 19.24M | 2.29M | -249K | |
Tangible asset value | 16.57M | 10.24M | 20.01M | 2.88M | 202K | |
Net current asset value | 16.09M | 9.46M | 19.24M | 1.73M | -533K | |
Invested capital | 0 | 0.04 | 0.01 | 0.28 | 2.77 | |
Average receivables | 2.83M | 1.3M | 42K | 14K | 29K | |
Average payables | 1.46M | 1.39M | 581K | 1.38M | 1.51M | |
Average inventory | 0.5 | 474K | 474K | 0.9 | 6.5K | |
Days sales outstanding | 81.68 | 222.01 | 154.66 | 15 | 267.67 | |
Days payables outstanding | 2.13K | 383.97 | 2.61K | 76.24K | 1.09K | |
Days of inventory on hand | 0 | 1.29K | 0 | 0.07 | 12.45 | |
Receivables turnover | 4.47 | 1.64 | 2.36 | 24.33 | 1.36 | |
Payables turnover | 0.17 | 0.95 | 0.14 | 0 | 0.33 | |
Inventory turnover | 426.51K | 0.28 | 0 | 5K | 29.31 | |
ROE | 0.17 | -0.81 | -0.69 | -6.44 | -96.84 | |
Capex per share | -8 | -1.58 | -0.87 | -0.03 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q2
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.01 | 0.03 | 0 | 0 | 0 | |
Net income per share | -3.27 | -2.71 | -2.83 | -2.76 | -2.64 | |
Operating cash flow per share | -3.67 | -2.45 | -2.49 | -2.12 | -2.08 | |
Free cash flow per share | -3.67 | -2.45 | -2.49 | -2.12 | -2.08 | |
Cash per share | 6.62 | 3.98 | 1.51 | 11.99 | 7.91 | |
Book value per share | 5.65 | 2.86 | 0.12 | 10.34 | 6 | |
Tangible book value per share | 5.65 | 2.86 | 0.12 | 10.34 | 6 | |
Share holders equity per share | 5.65 | 2.86 | 0.12 | 10.34 | 6 | |
Interest debt per share | 0.44 | 0.38 | 0.34 | 0.22 | 0.17 | |
Market cap | 4.6M | 5.88M | 6.68M | 6.52M | 8.32M | |
Enterprise value | -5.25M | -51.96K | 4.76M | -18.85M | -11.63M | |
P/E ratio | -0.22 | -0.33 | -0.36 | -0.27 | -0.31 | |
Price to sales ratio | 328.52 | 108.82 | 954.1 | 0 | 0 | |
POCF ratio | -0.79 | -1.46 | -1.63 | -1.42 | -1.55 | |
PFCF ratio | -0.79 | -1.46 | -1.63 | -1.42 | -1.55 | |
P/B Ratio | 0.51 | 1.25 | 33.06 | 0.29 | 0.54 | |
PTB ratio | 0.51 | 1.25 | 33.06 | 0.29 | 0.54 | |
EV to sales | -375.19 | -0.96 | 680.1 | 0 | 0 | |
Enterprise value over EBITDA | 0.96 | 0.01 | -1.05 | 3.21 | 1.69 | |
EV to operating cash flow | 0.9 | 0.01 | -1.16 | 4.12 | 2.17 | |
EV to free cash flow | 0.9 | 0.01 | -1.16 | 4.12 | 2.17 | |
Earnings yield | -1.13 | -0.76 | -0.7 | -0.91 | -0.82 | |
Free cash flow yield | -1.27 | -0.69 | -0.61 | -0.7 | -0.64 | |
Debt to equity | 0.08 | 0.13 | 2.77 | 0.02 | 0.03 | |
Debt to assets | 0.06 | 0.08 | 0.13 | 0.02 | 0.02 | |
Net debt to EBITDA | 1.81 | 1.4 | 0.42 | 4.32 | 2.91 | |
Current ratio | 4.41 | 2.35 | 0.94 | 5.83 | 3.62 | |
Interest coverage | -623.33 | -620.14 | -568.75 | 979 | -1.15K | |
Income quality | 1.08 | 0.92 | 0.88 | 0.77 | 0.79 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 133.07 | 22.74 | 195.86 | 0 | 0 | |
Research and developement to revenue | 268.64 | 58.65 | 455.14 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | -0.14 | 0 | 0 | |
Capex to depreciation | 0 | 0 | -0.01 | 0 | 0 | |
Stock based compensation to revenue | -3.43 | 1.31 | 18.14 | 0 | 0 | |
Graham number | 20.41 | 13.21 | 2.8 | 25.34 | 18.88 | |
ROIC | -0.52 | -0.74 | -3.39 | -0.25 | -0.42 | |
Return on tangible assets | -0.44 | -0.54 | -1.04 | -0.22 | -0.32 | |
Graham Net | 4.82 | 1.88 | -1.06 | 9.81 | 5.64 | |
Working capital | 8.49M | 4.24M | -249K | 21.88M | 15.05M | |
Tangible asset value | 8.99M | 4.71M | 202K | 22.31M | 15.47M | |
Net current asset value | 8.06M | 3.89M | -533K | 21.67M | 14.91M | |
Invested capital | 0.08 | 0.13 | 2.77 | 0.02 | 0.03 | |
Average receivables | 35.5K | 62K | 55.5K | 54K | 53K | |
Average payables | 569.5K | 583K | 887.5K | 1.33M | 2.07M | |
Average inventory | 0.15 | 7K | 13.5K | 13K | 13.5K | |
Days sales outstanding | 437.14 | 93.33 | 707.14 | 0 | 0 | |
Days payables outstanding | 1.17K | 1.79K | 1.22K | -1.3K | 235.71K | |
Days of inventory on hand | 0 | 39.38 | 13.93 | -11.04 | 1.26K | |
Receivables turnover | 0.21 | 0.96 | 0.13 | 0 | 0 | |
Payables turnover | 0.08 | 0.05 | 0.07 | -0.07 | 0 | |
Inventory turnover | -205K | 2.29 | 6.46 | -8.15 | 0.07 | |
ROE | -0.58 | -0.95 | -23.07 | -0.27 | -0.44 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
BNTC Frequently Asked Questions
What is Benitec Biopharma Inc. stock symbol ?
Benitec Biopharma Inc. is a US stock , located in Hayward of Ca and trading under the symbol BNTC
What is Benitec Biopharma Inc. stock quote today ?
Benitec Biopharma Inc. stock price is $5.13 today.
Is Benitec Biopharma Inc. stock public?
Yes, Benitec Biopharma Inc. is a publicly traded company.